Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes: results from the GEMINI Trial.

Research output: Contribution to journalArticle

Jackson T. Wright, George L. Bakris, David S.H. Bell, Vivian Fonseca, Richard E. Katholi, Janet B. McGill, Franz H. Messerli, Robert A. Phillips, Philip Raskin, Fred K. Holdbrook, Mary Ann Lukas, Malini Iyengar

The effects of beta-blockade in addition to more specific renin-angiotensin system (RAS) blockers on blood pressure (BP) in patients with diabetes are described. After washout of medications other than angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, patients were titrated to a BP level <130/80 mm Hg using therapy with carvedilol 6.25 to 25 mg bid (n=498) or metoprolol tartrate 50 to 200 mg bid (n=737). At the end of the beta-blocker titration period, a BP level <130/80 mm Hg was achieved in 37% of carvedilol-treated and 36% of metoprolol-treated participants who continued to receive a renin-angiotensin system blocker. In the approximately 60% of participants in whom a BP level <130/80 mm Hg was not attained with renin-angiotensin system blockade plus beta-blockade, hydrochlorothiazide was added in 43% and 44% of carvedilol and metoprolol groups, respectively; 25% (both arms) also required a calcium channel blocker. Among those in whom goal BP was not achieved, 42% of carvedilol- and 40% of metoprolol-treated participants were not titrated to the highest dose of beta-blocker. The use of carvedilol compared with metoprolol did not effect glycemic control.

Original languageEnglish (US)
Pages (from-to)842-849
Number of pages8
JournalJournal of clinical hypertension (Greenwich, Conn.)
Volume9
Issue number11
DOIs
StatePublished - Jan 1 2007

PMID: 17978591

Altmetrics

Cite this

Standard

Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes : results from the GEMINI Trial. / Wright, Jackson T.; Bakris, George L.; Bell, David S.H.; Fonseca, Vivian; Katholi, Richard E.; McGill, Janet B.; Messerli, Franz H.; Phillips, Robert A.; Raskin, Philip; Holdbrook, Fred K.; Lukas, Mary Ann; Iyengar, Malini.

In: Journal of clinical hypertension (Greenwich, Conn.), Vol. 9, No. 11, 01.01.2007, p. 842-849.

Research output: Contribution to journalArticle

Harvard

Wright, JT, Bakris, GL, Bell, DSH, Fonseca, V, Katholi, RE, McGill, JB, Messerli, FH, Phillips, RA, Raskin, P, Holdbrook, FK, Lukas, MA & Iyengar, M 2007, 'Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes: results from the GEMINI Trial.' Journal of clinical hypertension (Greenwich, Conn.), vol. 9, no. 11, pp. 842-849. https://doi.org/10.1111/j.1524-6175.2007.07251.x

APA

Wright, J. T., Bakris, G. L., Bell, D. S. H., Fonseca, V., Katholi, R. E., McGill, J. B., ... Iyengar, M. (2007). Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes: results from the GEMINI Trial. Journal of clinical hypertension (Greenwich, Conn.), 9(11), 842-849. https://doi.org/10.1111/j.1524-6175.2007.07251.x

Vancouver

Wright JT, Bakris GL, Bell DSH, Fonseca V, Katholi RE, McGill JB et al. Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes: results from the GEMINI Trial. Journal of clinical hypertension (Greenwich, Conn.). 2007 Jan 1;9(11):842-849. https://doi.org/10.1111/j.1524-6175.2007.07251.x

Author

Wright, Jackson T. ; Bakris, George L. ; Bell, David S.H. ; Fonseca, Vivian ; Katholi, Richard E. ; McGill, Janet B. ; Messerli, Franz H. ; Phillips, Robert A. ; Raskin, Philip ; Holdbrook, Fred K. ; Lukas, Mary Ann ; Iyengar, Malini. / Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes : results from the GEMINI Trial. In: Journal of clinical hypertension (Greenwich, Conn.). 2007 ; Vol. 9, No. 11. pp. 842-849.

BibTeX

@article{ce02f1a0ed1f40bb869f66bb687419cc,
title = "Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes: results from the GEMINI Trial.",
abstract = "The effects of beta-blockade in addition to more specific renin-angiotensin system (RAS) blockers on blood pressure (BP) in patients with diabetes are described. After washout of medications other than angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, patients were titrated to a BP level <130/80 mm Hg using therapy with carvedilol 6.25 to 25 mg bid (n=498) or metoprolol tartrate 50 to 200 mg bid (n=737). At the end of the beta-blocker titration period, a BP level <130/80 mm Hg was achieved in 37{\%} of carvedilol-treated and 36{\%} of metoprolol-treated participants who continued to receive a renin-angiotensin system blocker. In the approximately 60{\%} of participants in whom a BP level <130/80 mm Hg was not attained with renin-angiotensin system blockade plus beta-blockade, hydrochlorothiazide was added in 43{\%} and 44{\%} of carvedilol and metoprolol groups, respectively; 25{\%} (both arms) also required a calcium channel blocker. Among those in whom goal BP was not achieved, 42{\%} of carvedilol- and 40{\%} of metoprolol-treated participants were not titrated to the highest dose of beta-blocker. The use of carvedilol compared with metoprolol did not effect glycemic control.",
author = "Wright, {Jackson T.} and Bakris, {George L.} and Bell, {David S.H.} and Vivian Fonseca and Katholi, {Richard E.} and McGill, {Janet B.} and Messerli, {Franz H.} and Phillips, {Robert A.} and Philip Raskin and Holdbrook, {Fred K.} and Lukas, {Mary Ann} and Malini Iyengar",
year = "2007",
month = "1",
day = "1",
doi = "10.1111/j.1524-6175.2007.07251.x",
language = "English (US)",
volume = "9",
pages = "842--849",
journal = "Journal of clinical hypertension (Greenwich, Conn.)",
issn = "1524-6175",
publisher = "Wiley",
number = "11",

}

RIS

TY - JOUR

T1 - Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes

T2 - Journal of clinical hypertension (Greenwich, Conn.)

AU - Wright, Jackson T.

AU - Bakris, George L.

AU - Bell, David S.H.

AU - Fonseca, Vivian

AU - Katholi, Richard E.

AU - McGill, Janet B.

AU - Messerli, Franz H.

AU - Phillips, Robert A.

AU - Raskin, Philip

AU - Holdbrook, Fred K.

AU - Lukas, Mary Ann

AU - Iyengar, Malini

PY - 2007/1/1

Y1 - 2007/1/1

N2 - The effects of beta-blockade in addition to more specific renin-angiotensin system (RAS) blockers on blood pressure (BP) in patients with diabetes are described. After washout of medications other than angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, patients were titrated to a BP level <130/80 mm Hg using therapy with carvedilol 6.25 to 25 mg bid (n=498) or metoprolol tartrate 50 to 200 mg bid (n=737). At the end of the beta-blocker titration period, a BP level <130/80 mm Hg was achieved in 37% of carvedilol-treated and 36% of metoprolol-treated participants who continued to receive a renin-angiotensin system blocker. In the approximately 60% of participants in whom a BP level <130/80 mm Hg was not attained with renin-angiotensin system blockade plus beta-blockade, hydrochlorothiazide was added in 43% and 44% of carvedilol and metoprolol groups, respectively; 25% (both arms) also required a calcium channel blocker. Among those in whom goal BP was not achieved, 42% of carvedilol- and 40% of metoprolol-treated participants were not titrated to the highest dose of beta-blocker. The use of carvedilol compared with metoprolol did not effect glycemic control.

AB - The effects of beta-blockade in addition to more specific renin-angiotensin system (RAS) blockers on blood pressure (BP) in patients with diabetes are described. After washout of medications other than angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, patients were titrated to a BP level <130/80 mm Hg using therapy with carvedilol 6.25 to 25 mg bid (n=498) or metoprolol tartrate 50 to 200 mg bid (n=737). At the end of the beta-blocker titration period, a BP level <130/80 mm Hg was achieved in 37% of carvedilol-treated and 36% of metoprolol-treated participants who continued to receive a renin-angiotensin system blocker. In the approximately 60% of participants in whom a BP level <130/80 mm Hg was not attained with renin-angiotensin system blockade plus beta-blockade, hydrochlorothiazide was added in 43% and 44% of carvedilol and metoprolol groups, respectively; 25% (both arms) also required a calcium channel blocker. Among those in whom goal BP was not achieved, 42% of carvedilol- and 40% of metoprolol-treated participants were not titrated to the highest dose of beta-blocker. The use of carvedilol compared with metoprolol did not effect glycemic control.

UR - http://www.scopus.com/inward/record.url?scp=38449096828&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38449096828&partnerID=8YFLogxK

U2 - 10.1111/j.1524-6175.2007.07251.x

DO - 10.1111/j.1524-6175.2007.07251.x

M3 - Article

VL - 9

SP - 842

EP - 849

JO - Journal of clinical hypertension (Greenwich, Conn.)

JF - Journal of clinical hypertension (Greenwich, Conn.)

SN - 1524-6175

IS - 11

ER -

ID: 16785158